Keyword: Joe Jimenez

Vas Narasimhan’s 2018 take-home pay suffered on bottom-of-the-barrel shareholder returns over three years, compared with its Big Pharma rivals.

Four Democratic senators have published a report rebutting Novartis' account of the details behind its consulting deal with Michael Cohen.

Former Novartis CEO Joe Jimenez was set to join the board of a leading hedge fund, but the plans are now on hold, WSJ reports.

Two people signed Novartis' contract with Michael Cohen, and now they've both left: Ex-CEO Joe Jimenez and GC Felix Ehrat, who stepped down Wednesday.

Novartis CEO Vas Narasimhan acknowledged the company “made a mistake” by striking a $1.2 million deal with Trump lawyer Michael Cohen.

After round-the-world scandals, it certainly appears Novartis has a systemic problem. But Vas Narasimhan has a clean slate—and he needs to use it.

Novartis' account of the Michael Cohen deal leaves plenty of unanswered questions.

Novartis insiders blame ex-CEO Joe Jimenez for a $1.2M contract with Trump attorney Michael Cohen—and they say Novartis was buying access, not advice.

Putting digital into Novartis' DNA is one of CEO Vas Narasimhan’s goals, and the drugmaker has just inked another deal that aims to do just that.

Incoming Novartis chief Vas Narasimhan outlined his big goals as CEO on Wednesday: Think drug launches and more drug launches.